ASCP Corner
Interested in submitting a proposal for the ASCP Corner?
Contact Leslie Citrome, MD, MPH, ASCP Corner Editor, at nntman@gmail.com.
ASCP Corner Guidelines: Leslie Citrome, MD, MPH, Editor
- Articles are limited to 1500 words excluding references.
Try to limit the number of references to no more than 30. - The best articles for the Corner are focused, timely, and teach the clinician. Essentially they are brief reviews.
- Authors should consider the 3 or 4 points they want to make before they start.
- Each article is peer-reviewed by experts within the topic being written about.
- Resident submissions are encouraged, provided that Faculty mentorship is obtained.
- Presubmission inquiries are always welcome - contact the editor at nntman@gmail.com
Issues of ASCP Corner
Comparing Prevalence of Burnout in Psychiatric Doctors Before and After the COVID-19 Pandemic: A Systematic Review and Meta-Analysis
The prevalence of burnout was 37.5% prior to the COVID-19 pandemic and 32.0% following the pandemic. The post Comparing Prevalence of Burnout in Psychiatric Doctors Before and After the COVID-19 Pandemic: A… Read more »
Source: Psychiatrist.com | Published: September 29, 2025 - 9:00 am
Effects of Interpersonal and Social Rhythm Therapy on Suicidal Ideation in Adults With Bipolar II Depression
There was no significant difference in suicidal ideation in those receiving IPSRT plus placebo vs IPSRT plus quetiapine. IPSRT has the potential to mitigate suicidal ideation in patients with bipolar II depression, regardless of… Read more »
Source: Psychiatrist.com | Published: September 29, 2025 - 9:00 am
Long-Term Nonprescription Use of Dexamethasone and Cyproheptadine With Metabolic and Endocrine Sequelae
This case provides rare insight into the complications and delayed recognition associated with long-term, nonpsychoactive substance misuse, despite overt harm and a family history of addiction treatment. The post Long-Term Nonprescription Use of Dexamethasone and Cyproheptadine With Metabolic… Read more »
Source: Psychiatrist.com | Published: September 25, 2025 - 9:00 am
Management of Neuropsychiatric Symptoms Associated With Morquio Syndrome
A 70-year-old man with Morquio syndrome presented with mood instability and behavioral changes and became a significant nursing challenge. The post Management of Neuropsychiatric Symptoms Associated With Morquio Syndrome appeared first on Psychiatrist.com… Read more »
Source: Psychiatrist.com | Published: September 25, 2025 - 9:00 am
Why Getting Major Depression Right Matters—For Mothers, Babies, and All of Us
Commenting on an FDA panel discussion on SSRI use during pregnancy, Dr Payne emphasizes the importance of precision when discussing treatments for mental health conditions. The post Why Getting Major Depression Right Matters—For Mothers, Babies, and All of… Read more »
Source: Psychiatrist.com | Published: September 24, 2025 - 9:00 am
Prioritizing Mental Health to Optimize Perinatal, Fetal, and Neonatal Outcomes
Following an FDA panel discussion on use of SSRIs in pregnancy, the authors highlight the need for balanced conversations and shared decision-making accounting for the risks of untreated disease for both mother and offspring. The post Prioritizing Mental Health to… Read more »
Source: Psychiatrist.com | Published: September 24, 2025 - 9:00 am
PSI Response: FDA Panel Discussion Regarding SSRIs in Pregnancy
A response from Postpartum Support International expressing concern about the July 2025 FDA panel discussion on SSRIs in pregnancy. The post PSI Response: FDA Panel Discussion Regarding SSRIs in Pregnancy appeared first on Psychiatrist.com… Read more »
Source: Psychiatrist.com | Published: September 24, 2025 - 9:00 am
Electroconvulsive Therapy for Refractory Auditory Hallucinations in Turner Syndrome
Turner syndrome, schizophrenia and MDD presented for an ECT evaluation after multiple pharmacologic treatments failed to control her refractory auditory hallucinations, which had persisted for approximately 4 years. The post Electroconvulsive Therapy for Refractory Auditory Hallucinations in… Read more »
Source: Psychiatrist.com | Published: September 23, 2025 - 9:00 am
Complicated Grief: Is There a Role for Naltrexone?
The authors discuss prolonged grief disorder and the use of medications like naltrexone as a potential treatment. The post Complicated Grief: Is There a Role for Naltrexone? appeared first on Psychiatrist.com… Read more »
Source: Psychiatrist.com | Published: September 23, 2025 - 9:00 am
Ketamine and Esketamine: Is There a Meaningful Clinical Difference?
The authors comment on a recent chart review by Meisner and colleagues. The post Ketamine and Esketamine: Is There a Meaningful Clinical Difference? appeared first on Psychiatrist.com… Read more »
Source: Psychiatrist.com | Published: September 22, 2025 - 9:00 am
Past Issues of ASCP Corner
Vol. 84, 2023
Mete Ercis, Aysegul Ozerdem, and Balwinder Singh
Vol. 83, 2022
- Thyroid Hormone Use in Mood Disorders: Revisiting the Evidence
Balwinder Singh and Vishnu Sundaresh - Best Practices for Starting Clozapine in Patients With Schizophrenia: How to Switch From the Prior Antipsychotic(s)
Georgios Schoretsanitis and Jose de Leon - Prioritizing Patient Preferences: A Practical Guide for Tailoring Treatment Choices in Interventional Psychiatry
Joshua Berman and Adrian Jacques Ambrose - Cardiovascular Health in Severe Mental Illness: Potential Role for Metformin
Sri Mahavir Agarwal and Nicolette Stogios - How to Make an Effective Offer of Clozapine
Jose M. Rubio and John M. Kane
Vol. 82, 2021
- Psychopharmacologists and the Medical, Legal, and Societal Problems of the Homeless Mentally Ill: An Opinion
Ira D. Glick, Jeff Berlant, and Neil Eisenberg - Second-Generation Antipsychotics and Suicide: A Commentary
Zachary D. Zuschlag - Investigational Treatment of Depressive Disorders With Neuroactive Steroids: Potential Implications for Premenstrual Dysphoric Disorder
Mercedes J. Szpunar and Marlene P. Freeman - Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 2: Review of the Evidence
Avinash Hosanagar, Joseph Cusimano, and Rajiv Radhakrishnan - Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 1: Psychopharmacology and Neurobiological Effects
Avinash Hosanagar, Joseph Cusimano, and Rajiv Radhakrishnan - Wrestling With Antidepressant Use in Bipolar Disorder: The Ongoing Debate
Joseph F. Goldberg, Andrew A. Nierenberg, and Dan V. Iosifescu
Vol. 81, 2020
- Long-Acting Injectable Antipsychotic Use During Pregnancy: A Brief Review and Concise Guide for Clinicians
Sarah A. Reinstein, Jessica Cosgrove, Tara Malekshahi, and Kristina M. Deligiannidis - Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder
Reilly R. Kayser - Not So Fast: Recent Successes and Failures in Treating Depression
Bashkim Kadriu, Zhi-De Deng, Christoph Kraus, Ioline D. Henter, Sarah H. Lisanby, and Carlos A. Zarate, Jr - Antipsychotic Polypharmacy in Schizophrenia: Why Not?
Daniel Guinart and Christoph U. Correll - Evidence-Based Treatment of Premenstrual Dysphoric Disorder: A Concise Review
Sara V. Carlini and Kristina M. Deligiannidis - Diets and Disorders: Can Foods or Fasting Be Considered Psychopharmacologic Therapies?
Christopher M. Palmer
Vol. 80, 2019
- Anti-Inflammatory Treatments for Major Depressive Disorder: What’s on the Horizon?
Manish Kumar Jha - Medical Marijuana: What Physicians Need to Know
Rajiv Radhakrishnan, Mohini Ranganathan, and Deepak Cyril D’Souza - Treatment-Resistant Schizophrenia
Justin Faden - Are There Effective Psychopharmacologic Treatments for PTSD?
Teddy J. Akiki, and Chadi G. Abdallah - Inaccurate Prescribing Warnings in Electronic Medical Record Systems: Results From an American Society of Clinical Psychopharmacology Membership Survey
Katharine A. Phillips and Leslie Citrome - When Further Pharmacotherapy Seems Futile
Joseph F. Goldberg
Vol. 79, 2018
- Psychiatric Disorders and Comorbid Cannabis Use: When Should We Be Concerned and What Can We Do About It?
Derek D. Satre, Brian Borsari, Andrew Tompkins, and Danielle Ramo - Psychiatric Disorders and Comorbid Cannabis Use: How Common Is It and What Is the Clinical Impact?
Derek D. Satre, Amber Bahorik, Tauheed Zaman, and Danielle Ramo - A Commentary on Existential Psychopharmacologic Clinical Practice: Advocating a Humanistic Approach to the “Med Check”
S. Nassir Ghaemi, Ira D. Glick, and James M. Ellison - Motivational Interviewing: Overcoming Disparities in Pharmacotherapy Engagement
Roberto Lewis-Fernández, Angela A. Coombs, Iván C. Balán, and Alejandro Interian - A Note from the ASCP President
Michael E. Thase - Depression With Mixed Features in Major Depressive Disorder: A New Diagnosis or There All Along?
Michael Ostacher and Trisha Suppes - Patients With Alcohol Use Disorder Co-Occurring With Depression and Anxiety Symptoms: Diagnostic and Treatment Initiation Recommendations
Ahmed N. Hassan
Vol. 78, 2017
- Management of New Onset Psychosis in the Postpartum Period
Amanda Tinkelman, Emily A. Hill, and Kristina M. Deligiannidis - Do You Order Pharmacogenetic Testing? Why?
Joseph F. Goldberg - Duration and Relevance of Untreated Psychiatric Disorders, 2: Nonpsychotic Psychiatric Disorders and Substance Use Disorders
Jose M. Rubio and Christoph U. Correll - Duration and Revelance of Untreated Psychiatric Disorders, 1: Psychotic Disorders
Jose M. Rubio and Christoph U. Correll
Vol. 76, 2015
- Narrowing the Gaps Between What We Know and What We Do in Psychiatry
A. John Rush - Recommendations for the Monitoring of Serum Concentrations of Antipsychotic Drugs in the Treatment of Schizophrenia
Leonardo V. Lopez and John M. Kane - Improving the Practice of Clinical Psychopharmacotherapy: The Process of Long-Term Management for Patients and Caregivers
Ira D. Glick and James M. Ellison - Bipolar Therapeutics Update 2014: A Tale of 3 Treatments
Terence A. Ketter, Po W. Wang, and Shefali Miller
Vol. 75, 2014
- Updates and Trends in the Treatment of Major Depressive Disorder
George I. Papakostas and Dawn F. Ionescu - Can We Bottle Psychosocial Treatments for Addiction? The Role of Oxytocin
Christopher S. Stauffe and Joshua D. Woolley - Hoarding Disorder: More Than Just a Problem of Too Much Stuff
Carol A. Mathews - Whatever Happened to New Treatments for Alzheimer’s Disease?
Davangere P. Devanand - Inflammatory Depression: A Trifecta of Trouble
Charles L. Raison - The Endocannabinoid System and Schizophrenia: Links to the Underlying Pathophysiology and to Novel Treatment Approaches
Swapnil Gupta, John D. Cahill, Mohini Ranganathan, and Christoph U. Correll - The ASCP Annual Meeting (NCDEU): A History
Maurizio Fava
Vol. 74, 2013
- The Role of Vitamin D in Depression: From a Curious Idea to a Therapeutic Option
Cédric Annweiler, Reza Rastmanesh, Stéphane Richard-Devantoy, and Olivier Beauchet - Decision Making and Antipsychotic Medication Treatment for Youth With Autism Spectrum Disorders: Applying Guidelines in the Real World
Stephanie H. Ameis, Patricia Corbett-Dick, Lynn Cole, and Christoph U. Correll - Antidepressant Use in Pregnancy and Risk of Autism Spectrum Disorders: A Critical Examination of the Evidence
Chittaranjan Andrade - Pulsed Intravenous Administration of Scopolamine Produces Rapid Antidepressant Effects and Modest Side Effects
Maura L. Furey and Carlos A. Zarate, Jr - Changes in the Diagnostic Criteria for Autism in DSM-5: Controversies and Concerns
Eric P. Hazen, Christopher J. McDougle, and Fred R. Volkmar - Bipolar Disorder and Attention-Deficit/Hyperactivity Disorder Comorbidity in Children and Adolescents: Evidence-Based Approach to Diagnosis and Treatment
Shefali Miller, Kiki D. Chang, and Terence A. Ketter - Current Status of Ketamine and Related Compounds for Depression
Daniel C. Mathews and Carlos A. Zarate, Jr - Lessons Learned From d-Cycloserine: The Promise and Limits of Drug Facilitation of Exposure Therapy
Thomas L. Rodebaugh and Eric J. Lenze - Reconsidering Chronic Hyponatremia in Psychosis
Richard C. Josiassen, Dawn M. Filmyer, Alexander G. Geboy, and Rita A. Shaughnessy - Monoamine Oxidase Inhibitors Revisited: What You Should Know
Joseph F. Goldberg and Michael E. Thase
Vol. 73, 2012
- Cardiovascular Disease and Bipolar Disorder: Risk and Clinical Implications
Holly A. Swartz and Andrea Fagiolini - Discordance Between Researchers and Patients in Defining Remission From Depression
Mark Zimmerman
Vol. 72, 2011
- Stepping Back to Step Forward: Lessons From the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
Amy T. Peters and Andrew A. Nierenberg - Assessing the Adequacy of Past Antidepressant Trials: A Clinician’s Guide to the Antidepressant Treatment Response Questionnaire
Martin Desseilles, Janet Witte, Trina E. Chang, Nadia Iovieno, Christina M. Dording, Heidi Ashih, Maren Nyer, Marlene P. Freeman, Maurizio Fava, and David Mischoulon - Rediscovering Adverse Anticholinergic Effects
Philip Gerretsen and Bruce G. Pollock - Number Needed to Treat: What It Is and What It Isn’t, and Why Every Clinician Should Know How to Calculate It
Leslie Citrome - Omega-3 Fatty Acids and Depression: From Cellular Mechanisms to Clinical Care
Marlene P. Freeman, and Mark H. Rapaport
Vol. 71, 2010
- New Antipsychotic Drugs: How Do Their Receptor-Binding Profiles Compare?
Elliott Richelson - Bereavement, Complicated Grief, and DSM, Part 2: Complicated Grief
Sidney Zisook, Naomi M. Simon, Charles F. Reynolds III, Ronald Pies, Barry Lebowitz, Ilanit Tal Young, Jennifer Madowitz, and M. Katherine Shear - Bereavement, Complicated Grief, and DSM, Part 1: Depression
Sidney Zisook, Charles F. Reynolds III, Ronald Pies, Naomi Simon, Barry Lebowitz, Jen Madowitz, Ilanit Tal-Young, and M. Katherine Shear - Therapeutic Drug Monitoring in Pregnant and Postpartum Women: Recommendations for SSRIs, Lamotrigine, and Lithium
Kristina M. Deligiannidis - Transcranial Magnetic Stimulation for Medication-Resistant Depression
Agustin G. Yip and Linda L. Carpenter - How to Efficiently Maintain Your Own Electronic Resource Library
Leslie Citrome and Stuart V. Moss
Vol. 70, 2009
- Reconceptualizing Medication Management: Implications for Training and Clinical Practice
John Q. Young and J. Craig Nelson - Do Glutamatergic Agents Represent a New Class of Antidepressant Drugs? Part 2
Gerard Sanacora - Do Glutamatergic Agents Represent a New Class of Antidepressant Drugs? Part 1
Gerard Sanacora - Genetic Studies of Drug Response and Side Effects in the STAR*D Study, Part 2
Holly A. Garriock and Steven P. Hamilton - Genetic Studies of Drug Response and Side Effects in the STAR*D Study, Part 1
Holly A. Garriockand Steven P. Hamilton - Suicide Risk and Psychopharmacology: Assessment and Management of Acute and Chronic Risk Factors
Scott A. Freeman - Adding Lithium or Anticonvulsants to Antipsychotics for the Treatment of Schizophrenia: Useful Strategy or Exercise in Futility?
Leslie Citrome - Second-Generation Antipsychotic-Associated Diabetes Mellitus and Diabetic Ketoacidosis: Mechanisms, Predictors, and Screening Need
Dan Cohen and Christoph U. Correll - All Antipsychotics Are Equal, but Some Are More Equal Than Others
Jan Volavka and Leslie Citrome - Breastfeeding and Antidepressants: Clinical Dilemmas and Expert Perspectives
Marlene P. Freeman - Why Aren’t MAOIs Used More Often?
Jan Fawcett
Vol. 69, 2008
- Is the Problem of a High Placebo Response Unique to Antidepressant Trials?
Arif Khan and Amritha Bhat - Qualifications for Recertification: An Important but Evolving Set of Standards
Mark Hyman Rapaport and Deborah J. Hales - The Search for Knowledge: Developing the American Psychiatric Association’s Practice Guideline for Major Depressive Disorder
Alan J. Gelenberg - Are Nutritional Supplements Ready for Prime Time?
David Mischoulon and Maurizio Fava - Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Lessons Learned
Sidney Zisook, Krauz Ganadjian, Christine Moutier, Richard Prather, and Sanjai Rao - Are Antidepressants Effective? What’s a Clinician to Think?
Craig Nelson, Michael E. Thase, and Arif Khan - Antipsychotic Polypharmacy, Part 2: Why Use 2 Antipsychotics When 1 Is Not Good Enough?
Christoph U. Correll - Antipsychotic Polypharmacy, Part 1: Shotgun Approach or Targeted Cotreatment?
Christoph U. Correll - What Constitutes Evidence-Based Pharmacotherapy for Bipolar Disorder? Part 2: Complex Presentations and Clinical Context
Joseph F. Goldberg - Balancing Risks: Dosing Strategies for Antidepressants Near the End of Pregnancy
Laura J. Miller, Jeffrey R. Bishop, James H. Fischer, Stacie E. Geller, and Carol Macmillan - State of the Society
Vol. 68, 2007
- What Constitutes Evidence-Based Pharmacotherapy for Bipolar Disorder? Part 1: First-Line Treatments
Joseph F. Goldberg , MD - Teaching and Practicing Psychopharmacology
John M. Kane - Worried Sick: Antidepressants, Stress, and Inflammation
Bruce Lydiard - Clinical Psychopharmacology of Pediatric Mood Stabilizer and Antipsychotic Treatment, Part 2: Methodological Considerations
Christoph U. Correll - Clinical Psychopharmacology of Pediatric Mood Stabilizer and Antipsychotic Treatment, Part 1: Challenges and Developments
Christoph U. Correll - Dual Dependency on Cocaine and Alcohol in Opiate Addicts: Treatment Options
Tracie Gardner and Thomas Kosten - Pharmacoepidemiology: Recent Findings and Challenges for Child and Adolescent Psychopharmacology
Julie Magno Zito - Psychopharmacology in the Emergency Room
Michael D. Jibson - Psychopharmacologic Treatment Response of HIV-Infected Patients to Antipsychotic Medications
Dinesh Singh and Karl Goodkin - Choice of Antipsychotic in HIV-Infected Patients
Dinesh Singh and Karl Goodkin - The Psychopharmacology of Violence With Emphasis on Schizophrenia, Part 2: Long-Term Treatment
Leslie Citrome - The Psychopharmacology of Violence With Emphasis on Schizophrenia, Part 1: Acute Treatment
Leslie Citrome
Vol. 67, 2006
- Measurement-Based Psychiatry: Definitions of Response, Remission, Stability, and Relapse in Schizophrenia
Stefan Leucht, MD, and John M. Kane - Combining Pharmacotherapy With Psychotherapeutic Management: Guidelines for Integration
Ira D. Glick - Buprenorphine: Reflections of an Addictions Psychiatrist
Jeffrey Selzer - FDA Post-Marketing Safety Decisions
Donald F. Klein - ASCP Administers 10th Certification Exam
ASCP Examination Committee - Female Sexual Dysfunctions: What Controversy?
Anita H. Clayton - Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
John M. Kane - Novel Transdermal Delivery Formulation of the Monoamine Oxidase Inhibitor Selegiline Nearing Release for Treatment of Depression
Michael E. Thase - Use of Atypical Antipsychotics: Observations From Clinical Practice
Scott A. Spier - Complex Chemical Concoctions
James W. Jefferson - Real-Life Switching Strategies With Second-Generation Antipsychotics
Christoph U. Correll
Vol. 66, 2005
- Real-Life Dosing With Second-Generation Antipsychotics
Christoph U. Correll - Sexual Function and Dysfunction During Treatment With Psychotropic Medications
Richard Balon - Metabolic Side Effects of Second-Generation Antipsychotics in Children and Adolescents: A Different Story?
Christoph U. Correll - Gender Differences in Clinical Psychopharmacology
Anita H. Clayton - Increased Risk of Cerebrovascular Adverse Events and Death in Elderly Demented Patients Treated With Atypical Antipsychotics: What’s a Clinician to Do?
Craig Nelson - Challenges and Opportunities in Teaching Psychopharmacology During Residency Training
Sidney Zisook, MD; Ira Glick, MD; and David A. Goldberg - Cultural Competence in Clinical Psychopharmacology
James W. Thompson - Reading Reports of Clinical Trial Results
John M. Kane